AU2018336017B2 - Anti-GD2 antibody for the treatment of neuroblastoma - Google Patents

Anti-GD2 antibody for the treatment of neuroblastoma Download PDF

Info

Publication number
AU2018336017B2
AU2018336017B2 AU2018336017A AU2018336017A AU2018336017B2 AU 2018336017 B2 AU2018336017 B2 AU 2018336017B2 AU 2018336017 A AU2018336017 A AU 2018336017A AU 2018336017 A AU2018336017 A AU 2018336017A AU 2018336017 B2 AU2018336017 B2 AU 2018336017B2
Authority
AU
Australia
Prior art keywords
antibody
iga
domain
ganglioside
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018336017A
Other languages
English (en)
Other versions
AU2018336017A1 (en
Inventor
Johannes Gerardus Maria EVERS
Jeannette Henrica Wilhelmina LEUSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TigaTx Inc
Original Assignee
TigaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TigaTx Inc filed Critical TigaTx Inc
Publication of AU2018336017A1 publication Critical patent/AU2018336017A1/en
Application granted granted Critical
Publication of AU2018336017B2 publication Critical patent/AU2018336017B2/en
Priority to AU2021236513A priority Critical patent/AU2021236513A1/en
Assigned to TIGATX, INC. reassignment TIGATX, INC. Request for Assignment Assignors: UMC UTRECHT HOLDING B.V.
Priority to AU2025201363A priority patent/AU2025201363A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2018336017A 2017-09-21 2018-09-21 Anti-GD2 antibody for the treatment of neuroblastoma Active AU2018336017B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021236513A AU2021236513A1 (en) 2017-09-21 2021-09-23 Anti-GD2 antibody for the treatment of neuroblastoma
AU2025201363A AU2025201363A1 (en) 2017-09-21 2025-02-26 Anti-GD2 antibody for the treatment of neuroblastoma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192476.4 2017-09-21
EP17192476 2017-09-21
PCT/NL2018/050629 WO2019059771A2 (en) 2017-09-21 2018-09-21 ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021236513A Division AU2021236513A1 (en) 2017-09-21 2021-09-23 Anti-GD2 antibody for the treatment of neuroblastoma

Publications (2)

Publication Number Publication Date
AU2018336017A1 AU2018336017A1 (en) 2020-04-09
AU2018336017B2 true AU2018336017B2 (en) 2021-06-24

Family

ID=59955406

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018336017A Active AU2018336017B2 (en) 2017-09-21 2018-09-21 Anti-GD2 antibody for the treatment of neuroblastoma
AU2021236513A Abandoned AU2021236513A1 (en) 2017-09-21 2021-09-23 Anti-GD2 antibody for the treatment of neuroblastoma
AU2025201363A Pending AU2025201363A1 (en) 2017-09-21 2025-02-26 Anti-GD2 antibody for the treatment of neuroblastoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021236513A Abandoned AU2021236513A1 (en) 2017-09-21 2021-09-23 Anti-GD2 antibody for the treatment of neuroblastoma
AU2025201363A Pending AU2025201363A1 (en) 2017-09-21 2025-02-26 Anti-GD2 antibody for the treatment of neuroblastoma

Country Status (12)

Country Link
US (2) US11866511B2 (https=)
EP (1) EP3684818A2 (https=)
JP (2) JP2020534370A (https=)
KR (1) KR20200059249A (https=)
CN (1) CN111278862A (https=)
AU (3) AU2018336017B2 (https=)
BR (1) BR112020005742A2 (https=)
CA (1) CA3076482A1 (https=)
IL (1) IL273454A (https=)
MX (1) MX2020003201A (https=)
SG (1) SG11202002581WA (https=)
WO (1) WO2019059771A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN111849904B (zh) * 2020-07-31 2021-05-04 浙江科途医学科技有限公司 神经母细胞瘤类器官的培养基、培养方法及移植体
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049643A2 (en) * 2006-10-27 2008-05-02 Charite - Universitätsmedizin Berlin Gd2 peptide mimotopes for anticancer vaccination

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
EP2578681B1 (en) 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
CN106414494B (zh) * 2013-11-12 2020-09-18 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
ES2768649T3 (es) * 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2
CN105732814B (zh) * 2016-03-08 2019-05-28 苏州大学 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用
EP3747438A1 (en) 2017-07-24 2020-12-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049643A2 (en) * 2006-10-27 2008-05-02 Charite - Universitätsmedizin Berlin Gd2 peptide mimotopes for anticancer vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEYER, S. ET AL, "Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting", MABS, (2015), vol. 8, no. 1, pages 87 - 98 *

Also Published As

Publication number Publication date
US20210179732A1 (en) 2021-06-17
KR20200059249A (ko) 2020-05-28
BR112020005742A2 (pt) 2020-10-13
US20200283541A1 (en) 2020-09-10
CN111278862A (zh) 2020-06-12
JP2020534370A (ja) 2020-11-26
AU2025201363A1 (en) 2025-03-20
EP3684818A2 (en) 2020-07-29
SG11202002581WA (en) 2020-04-29
MX2020003201A (es) 2020-08-13
AU2021236513A1 (en) 2021-10-21
CA3076482A1 (en) 2019-03-28
JP2024023238A (ja) 2024-02-21
WO2019059771A3 (en) 2019-10-10
US11866511B2 (en) 2024-01-09
NZ762835A (en) 2024-12-20
IL273454A (en) 2020-05-31
WO2019059771A2 (en) 2019-03-28
AU2018336017A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
AU2018336017B2 (en) Anti-GD2 antibody for the treatment of neuroblastoma
JP7235733B2 (ja) Ｐｄ－１に特異的に結合する抗体、及び使用方法
TWI878213B (zh) 對cd70具特異性抗體及其用途
KR101323455B1 (ko) 푸코실 잔기가 결여된 ｃｄ30에 대한 단클론 항체
CN108368510B (zh) 特异性结合人cd40的激动性抗体和使用方法
TWI522366B (zh) 與ｃｘｃｒ４結合之人抗體及彼之用途
JP7451520B2 (ja) ヒト化抗ＳＩＲＰα抗体
KR20160126027A (ko) 급성 림프아구성 백혈병을 치료하기 위한 항-cd38 항체
EP3068798B1 (en) Human igg1 derived antibody with pro-apoptotic activity
JP7490923B2 (ja) 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
US20230235055A1 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
EA036927B1 (ru) Конъюгированные антитела против ly75 для лечения рака
JP2007530076A (ja) Ｉｒｔａ−５抗体およびその使用
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
US20230022731A1 (en) Engineered antibodies and methods of treatment
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
CN101233156A (zh) Cd19抗体及其用途
JP2024503394A (ja) ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント
KR102955590B1 (ko) 인간화 항-SIRPα 항체
KR20250017237A (ko) 항-tnfr2 항체 및 그의 사용 방법

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LEUSEN, JEANNETTE HENRICA WILHELMINA AND EVERS, JOHANNES GERARDUS MARIA

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TIGATX, INC.

Free format text: FORMER OWNER(S): UMC UTRECHT HOLDING B.V.